HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

948.605

+12.6651.35%

Number of Gainers:13

Number of Losers:4

Number of Flat:- -

PE:- -

High:962.137

Open:936.902

Low:936.902

Close:935.940

Volume:459.12M

Turnover:3.85B

Market Cap:638.41B

Float Cap:531.33B

Loading ...

Hong Kong Stock Flash | Baiyunshan (00874) Drops Nearly 6% After Results, Net Profit Falls 16.7% in H1 Due to Higher R&D Spending

Ascletis Pharma Slips on Expecting Deeper H1 Loss on R&D Expenses

Sinopharm Group's Profit Declines 2% in H1

MT Newswires Live

Guangzhou Baiyunshan Pharma's Profit Falls 17% in H1

MT Newswires Live

Sinopharm Interim Revenue Edges Down on Softness in Pharmaceutical Distribution Business

Sinopharm Proposes Re-Election of Lian Wanyong, Yang Binghua as Executive Directors

Sinopharm Group H1 Revenue RMB 282,799.6 Million

THOMSON REUTERS

Sinopharm H1 Net Profit Drops 2.95% to RMB 5.18 Billion; Revenue Slips 1.13% to RMB 282.8 Billion

JD Health International (SEHK:6618) Could Be 43% Undervalued As Half Year Profit Rises

Simply Wall St.

Dunhuang's Medical Heritage Blends into Tourism, Boosting Wellness Travel Along the Silk Road

mRNA Vaccine Breakthrough: From Prevention to Treatment, a Historic Leap in Oncology

Weak Dollar and Shifting Tech Narratives: Strategists Favor Resources and Pharma

Alibaba's Record HK$80 Billion Share Placement: A 3.6%-9% Discount Strategy Unveiled

BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating

UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating

Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance

CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Simply Wall St.

Ping An Healthcare And Technology (SEHK:1833) Reported Profits, Is The Stock Fully Priced?

Simply Wall St.

Sino Biopharmaceutical (SEHK:1177) Could Be 66% Below Fair Value As Earnings Lift Interest

Simply Wall St.

Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/BK1515/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":948.605,"timestamp":1787724654601,"preClose":935.94037,"halted":0,"volume":459116111,"delay":0,"changeRate":0.013531,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":12.664612,"latestTime":"08-26 14:10:56","open":936.9023,"high":962.13654,"low":936.9023,"amount":3846262025,"amplitude":0.026961,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787731800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787707800000,1787716800000],[1787720400000,1787731200000]],"pbRate":1.404704,"peRate":17.150171,"turnoverRate":0.006288,"increases":13,"decrements":4,"flats":0,"marketCap":638405644416,"floatMarketCap":531332271872},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":962.13654,"amplitude":0.026961,"preClose":935.94037,"low":936.9023,"pbRate":"1.404704","latestPrice":948.605,"volume":459116111,"delay":0,"open":936.9023,"prevYearClose":1190.107,"prevWeekClose":942.615,"prevMonthClose":925.972,"prevQuarterClose":802.777,"fiveDayClose":905.419,"twentyDayClose":946.773,"sixtyDayClose":944.904,"secType":"PLATE","market":"HK","turnoverRate":0.006288,"peRate":17.150171,"marketCap":638405644416,"floatMarketCap":531332271872,"timestamp":1787724654601,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":13,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1150872953","title":"Hong Kong Stock Flash | Baiyunshan (00874) Drops Nearly 6% After Results, Net Profit Falls 16.7% in H1 Due to Higher R&D Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=1150872953","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150872953?lang=en_us&edition=fundamental","pubTime":"2026-08-24 14:49","pubTimestamp":1787554167,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) saw its shares tumble nearly 6% in Hong Kong trading following the release of its interim results, with the stock down 5.64% to HK$14.22 at the time of writing, on a turnover of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","600332","BK1191","BK4585","BK0070","BK0028","BK0196","00874","BK4588","BK0175","BK0188","BK1606","KCAI","BK1515","BK1197","BK0239","BK0096","VXUS","BK0097","BK0183","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661240309","title":"Ascletis Pharma Slips on Expecting Deeper H1 Loss on R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661240309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661240309?lang=en_us&edition=fundamental","pubTime":"2026-08-24 11:43","pubTimestamp":1787542991,"startTime":"0","endTime":"0","summary":"BUZZ-Ascletis Pharma slips on expecting deeper H1 loss on R&D expenses** Shares of Ascletis Pharma Inc1672.HKslip 4.5% to HK$9.565, on track for the biggest one-day pct drop since August 10** The viral diseases and oncology focused pharmaceutical products developerexpects to record net lossof 319.7 million yuan  six months ended in June, as compared with a loss of 88 million yuan the same period a year ago** Company said deeper loss is due to significant increase in research and development expenses as it advances its comprehensive metabolic disease pipeline, including both small molecules and peptides** YTD, stock down 15.9%, while Hang Seng Biotech Index.HSBIOup 9.9%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L03A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661024436","title":"Sinopharm Group's Profit Declines 2% in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2661024436","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661024436?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:10","pubTimestamp":1787533855,"startTime":"0","endTime":"0","summary":"Sinopharm Group's  profit attributable to owners of the parent fell 1.8% in the first six months of 2026 to 3.40 billion yuan from 3.47 billion yuan a year ago, according to a Monday filing to the Hong Kong stock exchange.Earnings per share declined to 1.09 yuan from 1.11 yuan a year earlier, the pharmaceutical company said.Revenue edged down 1.1% to 282.8 billion yuan from 286.04 billion yuan a year ago.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1500","LU1115378108.SGD","BK1197","LU0640798160.USD","BK1515","FCA","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661244886","title":"Guangzhou Baiyunshan Pharma's Profit Falls 17% in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2661244886","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661244886?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:04","pubTimestamp":1787533464,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  posted an attributable net profit of 2.10 billion yuan for the first half of 2026, down 17% from 2.52 billion yuan a year earlier.Earnings per share rose to at 1.289 yuan from 1.548 yuan in the year-ago period, according to a Friday Hong Kong bourse filing.Revenue increased 0.61% year over year to 42.1 billion yuan from 41.8 billion yuan.The company proposed a cash dividend of 0.30 yuan per share, inclusive of tax, to all shareholders.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK1515","BK0070","BK1191","00874","FCA","BK0097","BK0175","BK0096","BK0183","BK0196","BK0239","BK1521","BK1606","BK0012","600332","BK0188","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661241804","title":"Sinopharm Interim Revenue Edges Down on Softness in Pharmaceutical Distribution Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241804","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661241804?lang=en_us&edition=fundamental","pubTime":"2026-08-24 08:02","pubTimestamp":1787529767,"startTime":"0","endTime":"0","summary":"Sinopharm interim revenue edges down on softness in pharmaceutical distribution businessOverviewChina pharmaceutical distributor's interim revenue declined slightly year-on-yearNet income attributable","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44K04V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDMCQ","LU0640798160.USD","HK0000306685.HKD","02696","HK0000306701.USD","BK4204","BK1587","00656","02137","BK1500","BK1197","BK1515","BK1161","HK0000320223.HKD","BK1230","LU1115378108.SGD","01099","BK1574","HK0000320264.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661224640","title":"Sinopharm Proposes Re-Election of Lian Wanyong, Yang Binghua as Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661224640","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661224640?lang=en_us&edition=fundamental","pubTime":"2026-08-24 06:22","pubTimestamp":1787523731,"startTime":"0","endTime":"0","summary":"Sinopharm proposes re-election of Lian Wanyong, Yang Binghua as executive directorsSinopharm flagged a board refresh, proposing to re-elect all current directors for a new three-year term starting Sep","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260823:nNDL5wd0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","LU0640798160.USD","LU1115378108.SGD","01099","BK1515","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661246495","title":"Sinopharm Group H1 Revenue RMB 282,799.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661246495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661246495?lang=en_us&edition=fundamental","pubTime":"2026-08-24 06:16","pubTimestamp":1787523367,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260823:nPLXXLTJCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1115378108.SGD","01099","BK1500","LU0640798160.USD","BK1197","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661246450","title":"Sinopharm H1 Net Profit Drops 2.95% to RMB 5.18 Billion; Revenue Slips 1.13% to RMB 282.8 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2661246450","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661246450?lang=en_us&edition=fundamental","pubTime":"2026-08-24 06:15","pubTimestamp":1787523312,"startTime":"0","endTime":"0","summary":"Sinopharm H1 net profit drops 2.95% to RMB 5.18 billion; revenue slips 1.13% to RMB 282.8 billionSinopharm posted profit for the period of RMB 5.18 billion, down 2.95% year-on-year; basic EPS slipped ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260823:nNDLdVNSF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","BK1515","01099","LU0640798160.USD","LU1115378108.SGD","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661224557","title":"JD Health International (SEHK:6618) Could Be 43% Undervalued As Half Year Profit Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2661224557","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661224557?lang=en_us&edition=fundamental","pubTime":"2026-08-24 01:17","pubTimestamp":1787505428,"startTime":"0","endTime":"0","summary":"Why JD Health International’s Latest Earnings Matter For Investors\nJD Health International (SEHK:6618) drew fresh attention after reporting half year 2026 earnings, with higher sales, net income and earnings per share compared with the same period a year earlier.\nSee our latest analysis for JD Health International.\nDespite the stronger half year earnings, JD Health International’s share price tells a mixed story. The stock is at HK$38.66 after a 1 day share price return of 1.63%, yet the year...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-international-sehk6618-could-be-43-undervalued-as","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-international-sehk6618-could-be-43-undervalued-as","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SGXZ62798434.SGD","BK1515","86618","BK1589","BK1591","SGXZ86797644.SGD","BK1142","BK1247","LU0456827905.SGD","BK1615","LU0051755006.USD","BK1583","06618","BK1571"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135663784","title":"Dunhuang's Medical Heritage Blends into Tourism, Boosting Wellness Travel Along the Silk Road","url":"https://stock-news.laohu8.com/highlight/detail?id=1135663784","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135663784?lang=en_us&edition=fundamental","pubTime":"2026-08-23 20:51","pubTimestamp":1787489466,"startTime":"0","endTime":"0","summary":"This summer, the rich tapestry of Dunhuang's medical culture—from the \"moxibustion charts\" painted on its ancient grotto walls to the \"prescription collections\" and the legendary \"immortal porridge\"...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","159938","BK1515","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119759096","title":"mRNA Vaccine Breakthrough: From Prevention to Treatment, a Historic Leap in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1119759096","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119759096?lang=en_us&edition=fundamental","pubTime":"2026-08-23 19:20","pubTimestamp":1787484034,"startTime":"0","endTime":"0","summary":"On August 19, 2026, the pharmaceutical world was set ablaze. US drug giants Moderna and Merck jointly announced the successful Phase III INTerpath-001 clinical trial of their personalized mRNA...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","MRNY","09939","BK1574","159938","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119594086","title":"Weak Dollar and Shifting Tech Narratives: Strategists Favor Resources and Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1119594086","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119594086?lang=en_us&edition=fundamental","pubTime":"2026-08-23 16:42","pubTimestamp":1787474551,"startTime":"0","endTime":"0","summary":"Founder Securities has released a research report indicating that the market showed a pattern of initial gains followed by losses this week. After a rapid rebound in the early period, major indices...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","03034","09939","VGT","03455","BK4585","07261","09086","09834","UDN","BK1515","07568","BK1147","07522","XLK","02834","TTTN","159938","DBND","UUP","BK4588","07266","BK1574","03086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102285695","title":"Alibaba's Record HK$80 Billion Share Placement: A 3.6%-9% Discount Strategy Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1102285695","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102285695?lang=en_us&edition=fundamental","pubTime":"2026-08-23 16:31","pubTimestamp":1787473875,"startTime":"0","endTime":"0","summary":"Alibaba has officially announced a new share issuance, with a placement size of HK$80 billion, representing approximately 4% of its total market capitalization. The offering comes with a discount...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1615","LU0821914370.USD","LU0329678170.USD","LU2399975544.HKD","LU2097828631.EUR","LU0235996351.USD","LU0307460666.USD","LU0594300179.USD","LU2097829019.USD","IE0032431581.USD","LU0823397285.USD","LU1048596156.SGD","LU0607220059.USD","HK0000151867.HKD","BK1588","LU1282648689.USD","IE00B0JY6N72.USD","LU1868838027.USD","LU0348783233.USD","IE00B0169N27.USD","LU1481107354.HKD","LU0211977185.USD","LU0762541174.USD","LU1044875133.USD","LU0856984785.SGD","LU2125910500.SGD","LU0502904849.HKD","LU1439103000.SGD","LU1770034418.SGD","LU0608807946.USD","LU0456846285.SGD","LU0348735423.USD","HK0000320223.HKD","LU0106959298.USD","IE00B5MMRT66.SGD","LU0516422952.EUR","LU0320764243.SGD","LU0634319403.HKD","LU0531970944.HKD","LU0106252389.USD","LU0229945570.USD","LU0345776255.USD","LU1880383366.USD","LU1224709979.USD","HBBD.SI","LU0132412106.USD","LU1719994722.HKD","BK1517","LU0918141705.HKD","IE00BZ08YR35.GBP","LU0516422366.SGD","LU1282651121.HKD","LU2476274308.USD","LU0594300419.USD","LU0244354667.USD","SG9999000327.SGD","ALBmain","LDEM","LU0873338254.USD","LU2097828557.USD","LU0348825331.USD","LU1688375341.USD","LU1813983027.USD","SG9999002828.SGD","SG9999006597.SGD","SGXZ86797644.SGD","LU0314109678.HKD","LU1880398471.USD","SGXZ62798434.SGD","LU0128522744.USD","LU0264606111.USD","LU2449936058.SGD","LU1769817179.HKD","LU0169518387.USD","LU0197773160.USD","LU1720050803.USD","LU1366334578.USD","BK1189","LU1323998911.USD","LU0700851271.USD","LU1880398554.USD","BK1521","LU0143863198.USD","BK1502","BK1575","IE00BZ08YS42.EUR","LU0149721374.USD","LU0165289439.USD","LU0197773673.USD","LU0254981946.USD","LU0210527791.USD","LU2125910849.SGD","LU0048388663.USD","LU0651946864.USD","LU0417516738.SGD","LU0173614495.USD","LU0791590937.USD","IE0034224299.USD","SG9999001093.SGD","HK0000107257.USD","LU0823413587.USD","LU2097828474.EUR","LU0345775950.USD","LU0455707207.USD","SGXZ90724238.SGD","LU1515016050.SGD","LU0359201612.USD","LU1568876251.USD","LU0589944569.HKD","LU2257852520.SGD","SG9999002463.SGD","IE00BMPRXN33.USD","LU0228367735.SGD","LU0541501648.USD","LU0127658192.USD","IE00BPRC5H50.USD","LU0499858438.USD","LU0540923850.HKD","SG9999004220.SGD","LU0231483743.USD","LU0359202008.SGD","LU1831875114.USD","BK1586","IE00BMPRXR70.SGD","LU2357305700.SGD","LU0348814723.USD","LU0675040207.SGD","LU2242644610.SGD","LU0049853897.USD","LU0143863784.USD","LU0328353924.USD","LU0588545490.SGD","LU0320764755.SGD","LU1051769294.HKD","LU1201861165.SGD","LU1251922891.USD","LU0630378429.USD","LU0384037296.USD","LU0052750758.USD","LU2488822045.USD","LU0228659784.USD","HK0000165453.HKD","LU0823397103.USD","HK0000320264.USD","LU0463099449.HKD","LU1303224171.USD","LU0348783662.USD","LU0543330483.HKD","LU1023057109.AUD","LU1316542783.SGD","LU0348784397.USD","SG9999001051.SGD","LU0259732245.USD","LU0348827113.USD","LU0488056044.USD","BK1515","BK1618","BK1571","LU0261950983.USD","LU0516423174.USD","LU0823038988.USD","LU0577902298.EUR","LU0054237671.USD","LU0737861772.HKD","BKF","LU0117841782.USD","LU0072462343.USD","SG9999001903.USD","LU0823039010.USD","IE00B3M56506.USD","LU0898667661.SGD","LU0315179316.USD","LU0572944931.SGD","LU0823040885.USD","LU1044874839.SGD","LU1981816686.USD","LU1188198961.HKD","BK1249","LU1051768304.USD","LU0084288322.USD","LU1366334651.USD","LU0577902538.SGD","BK1247","89988","LU3063872942.SGD","LU0871576103.HKD","LU1960683339.HKD","LU1115378108.SGD","BK1591","BK1142","HK0000286598.CNH","LU0348805143.USD","LU0047713382.USD","LU1655091459.SGD","LU0320764599.SGD","LU0163747925.USD","LU0029875118.USD","LU1242518931.SGD","LU1328615791.USD","LU0359201885.HKD","LU0441854154.USD","LU0130103400.USD","LU0039217434.USD","LU0516423091.SGD","LU0823041008.USD","LU0650527681.SGD","LU0043850808.USD","LU0762542818.HKD","LU1769817096.USD","LU0543330566.HKD","LU0577902454.USD","LU0315178854.USD","LU0572939691.SGD","IE00B543WZ88.USD","BK1608","SG9999002562.SGD","IE0008368304.USD","LU0164865239.USD","LU0196878994.USD","LU0329678337.USD","LU0214875030.USD","LU0979878070.USD","LU0048597586.USD","LU0128522157.USD","LU0456827905.SGD","IE00BZ08YT58.USD","LU0918141887.USD","LU2293587155.HKD","LU0029874905.USD","LU0784639295.USD","LU0251144936.SGD","LU1956131251.USD","LU0588545730.USD","LU1642822792.SGD","LU0577902611.USD","LU0541502299.USD","LU1568876335.HKD","LU0061477393.USD","LU1808992512.USD","LU0572940350.SGD","LU2039709279.SGD","00241","LU0651947912.USD","LU1770036033.HKD","LU0417516902.SGD","LU1044876610.USD","LU0823413660.USD","LU0862451753.SGD","LU2778985437.USD","LU0868486357.SGD","LU2087589342.USD","LU1282651048.USD","LU0648000940.SGD","LU0890818403.SGD","LU1880383440.USD","SG9999000459.SGD","BK1501","LU0181495838.USD","LU1810669033.SGD","LU0326950275.SGD","LU1993786604.SGD","LU1720051108.HKD","LU0640798160.USD","LU0561508036.HKD","LU0886674414.USD","LU0588545904.SGD","LU0797268264.HKD","LU1282649810.SGD","LU0630378692.HKD","LU1328277881.USD","LU0588546209.SGD","LU0593848301.USD","LU2097828714.EUR","LU2097828805.USD","LU0293314216.USD","LU0865486749.SGD","LU0611395673.USD","LU0819121731.USD","LU0831103253.SGD","LU0531971595.HKD","LU1048588211.SGD","LU2152927971.USD","LU0831093199.SGD","LU2476274720.SGD","LU0791591158.USD","LU0051755006.USD","LU0708995583.HKD","BK1610","LU2045819591.USD","LU0577902371.SGD","LU0605514214.HKD","LU0477156797.USD","KWEB","LU1961090484.USD","SG9999014674.SGD","LU0396098781.USD","LU0708995153.HKD","LU0737861699.HKD","BK1617","LU0417516571.SGD","LU0348788117.USD","LU0828237510.HKD","LU0164872284.USD","LU0469268626.HKD","BK1589","LU0287142896.SGD","LU1048484197.HKD","LU0862451837.USD","FDNI","LU0449509016.USD","LU1196710864.SGD","LU0516422440.USD","LU0672654166.SGD","LU0819123356.HKD","BK1584","LU0048580855.USD","LU0828237940.HKD","LU0642271901.SGD","LU1282649141.HKD","LU0431992006.USD","LU0608807433.USD","LU0210526637.USD","LU1242518857.USD","HK0000306701.USD","LU0106259558.USD","LU1105468828.SGD","LU2226246903.HKD","LU0499858602.USD","LU0449515922.USD","LU1211504680.USD","LU0164880469.USD","LU2294711473.HKD","LU0130518102.USD","LU0823426308.USD","LU1794554557.SGD","LU0327786744.USD","LU0370786039.SGD","LU0096374516.USD","LU0648948544.HKD","LU0348816934.USD","LU1504937902.USD","LU1548497426.USD","SG9999001226.SGD","CXSE","IE0003895053.USD","BABA","LU0823426480.USD","LU1282649067.USD","LU1224444064.USD","SG9999006514.SGD","LU0117844026.USD","LU1720051017.SGD","SG9999001689.USD","09988","LU0762540952.USD","LU1807302812.USD","LU0140636845.USD","LU0011963245.USD","LU0149534421.HKD","LU1868837565.USD","LU0054450605.USD","LU0261947096.USD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128964959","title":"BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1128964959","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128964959?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:50","pubTimestamp":1787460626,"startTime":"0","endTime":"0","summary":"BofA Securities has released a research report indicating that CSPC PHARMA (01093) saw its total revenue and attributable net profit surge by 40.1% and 139.2% year-on-year, respectively, reaching RMB...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328277881.USD","LU0501845795.SGD","IE00BZ08YT58.USD","KURE","LU0314109678.HKD","01093","SG9999004220.SGD","LU1993786604.SGD","LU1008478684.HKD","IE00B543WZ88.USD","LU1226287792.SGD","BK1191","LU2039709279.SGD","IE00B031HY20.USD","LU0880133367.SGD","LU1226288170.HKD","LU1152091168.USD","LU1951186391.HKD","LU0072913022.USD","LU0326950275.SGD","IE0008368742.USD","BK1521","LU1226287529.USD","IE00BZ08YS42.EUR","LU1960683339.HKD","LU0315179316.USD","EWH","LU0067412154.USD","LU1813983027.USD","LU0140636845.USD","IE0008369823.USD","LU1152091754.HKD","LU1807302812.USD","BK1515","HK0000165453.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","IE00BZ08YR35.GBP","LU1226287875.USD","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110238919","title":"UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1110238919","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110238919?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:40","pubTimestamp":1787460024,"startTime":"0","endTime":"0","summary":"UBS has released a research report reiterating its \"Buy\" rating on CSPC PHARMA (01093) and raising its target price from HK$10.9 to HK$11.8. The adjustment reflects the company's increased R&D...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288170.HKD","LU1008478684.HKD","IE00BZ08YS42.EUR","KURE","LU1960683339.HKD","LU1993786604.SGD","LU2039709279.SGD","IE0008369823.USD","BK1515","LU0067412154.USD","LU0501845795.SGD","LU1807302812.USD","LU1951186391.HKD","IE00B031HY20.USD","LU1152091754.HKD","LU1226287875.USD","LU0880133367.SGD","BK1521","LU1813983027.USD","LU0326950275.SGD","LU0140636845.USD","LU0314109678.HKD","IE0008368742.USD","LU0072913022.USD","LU1226287792.SGD","EWH","LU1226288253.USD","LU1328277881.USD","SG9999004220.SGD","HK0000165453.HKD","01093","BK1191","IE00BZ08YR35.GBP","LU0315179316.USD","IE00B543WZ88.USD","LU1152091168.USD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162911841","title":"Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance","url":"https://stock-news.laohu8.com/highlight/detail?id=1162911841","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162911841?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:30","pubTimestamp":1787459445,"startTime":"0","endTime":"0","summary":"Goldman Sachs has released a research note reaffirming its \"Buy\" rating on CSPC Pharma (01093), while raising its profit forecasts for the 2026 to 2028 period by 0.2% to 1.7%. The investment bank has...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","IE0008368742.USD","IE00B543WZ88.USD","LU0140636845.USD","LU1328277881.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU0501845795.SGD","IE00BZ08YT58.USD","LU1813983027.USD","SG9999004220.SGD","LU1951186391.HKD","LU0314109678.HKD","LU0880133367.SGD","LU2039709279.SGD","BK1515","LU1226288170.HKD","BK1191","LU1226288253.USD","01093","IE00B5MMRT66.SGD","LU1152091168.USD","LU1993786604.SGD","LU1226287875.USD","LU1807302812.USD","LU1226287792.SGD","HK0000165453.HKD","EWH","IE00B031HY20.USD","LU0315179316.USD","LU0072913022.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1521","LU1226287529.USD","LU0067412154.USD","IE0008369823.USD","LU1008478684.HKD","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661217309","title":"CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2661217309","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661217309?lang=en_us&edition=fundamental","pubTime":"2026-08-23 08:56","pubTimestamp":1787446588,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited ( HKG:1093 ) defied analyst predictions to release its half-year results, which were...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-limited-beat-analyst-estimates-see","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-limited-beat-analyst-estimates-see","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0501845795.SGD","IE0008368742.USD","LU0315179316.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU0314109678.HKD","VGFPF","FEBU","BK1521","LU0140636845.USD","01093","LU1960683339.HKD","JOYT","LU0880133367.SGD","SG9999004220.SGD","DECU","LU1226287792.SGD","LU0326950275.SGD","VOTE","IE00BZ08YT58.USD","LU1152091168.USD","IE0008369823.USD","LU1951186391.HKD","RGLO","LU1813983027.USD","IE00B5MMRT66.SGD","GXDW","LU1226288170.HKD","LU1993786604.SGD","BK1515","LU1226287529.USD","LU0072913022.USD","PMDE","LU0067412154.USD","LU1226287875.USD","LU1152091754.HKD","LU1328277881.USD","LU1008478684.HKD","BK1191","LU1226288253.USD","LU1807302812.USD","IE00B031HY20.USD","LU2039709279.SGD","IE00BZ08YR35.GBP","KURE","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661219885","title":"Ping An Healthcare And Technology (SEHK:1833) Reported Profits, Is The Stock Fully Priced?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661219885","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661219885?lang=en_us&edition=fundamental","pubTime":"2026-08-22 17:23","pubTimestamp":1787390617,"startTime":"0","endTime":"0","summary":"Ping An Healthcare and Technology (SEHK:1833) reported half year 2026 earnings with sales of CNY 2,483.83 million and net income of CNY 219.33 million, alongside basic and diluted EPS of CNY 0.10.\nSee our latest analysis for Ping An Healthcare and Technology.\nThe earnings release on 18 August has come after a weak stretch for Ping An Healthcare and Technology, with the share price at HK$6.735 and the year-to-date share price return down 53.81%, while the 3-year total shareholder return is...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-1833/ping-an-healthcare-and-technology-shares/news/ping-an-healthcare-and-technology-sehk1833-reported-profits","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-1833/ping-an-healthcare-and-technology-shares/news/ping-an-healthcare-and-technology-sehk1833-reported-profits","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4137","JOYT","RGLO","FEBU","BK1615","DCF","LABU","LU0029874061.USD","VGFPF","BK1617","BK1571","LU0128526141.USD","BK4581","XBI","BK1219","BK4585","01833","BK1142","BK1247","VOTE","BK4588","PMDE","HCSG","BK1515","DECU","GXDW","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661216000","title":"Sino Biopharmaceutical (SEHK:1177) Could Be 66% Below Fair Value As Earnings Lift Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2661216000","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661216000?lang=en_us&edition=fundamental","pubTime":"2026-08-22 16:18","pubTimestamp":1787386734,"startTime":"0","endTime":"0","summary":"Half year earnings update and why Sino Biopharmaceutical stock is in focus\nSino Biopharmaceutical (SEHK:1177) recently reported half year 2026 earnings, with sales of CNY 19,444.36 million and net income of CNY 3,434.6 million. Earnings per share from continuing operations also edged higher versus a year earlier.\nSee our latest analysis for Sino Biopharmaceutical.\nThe latest earnings release appears to have sharpened investor focus on Sino Biopharmaceutical, with the stock posting a 3.80% 1...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/sino-biopharmaceutical-sehk1177-could-be-66-below-fair-value","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/sino-biopharmaceutical-sehk1177-could-be-66-below-fair-value","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GXDW","VGFPF","IE00BZ08YR35.GBP","01177","IE00BZ08YT58.USD","BK1521","BK1589","DECU","HK0000165453.HKD","VOTE","PMDE","RGLO","IE00BZ08YS42.EUR","JOYT","BK1515","FEBU","BK1191","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661901362","title":"Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661901362","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661901362?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:15","pubTimestamp":1787346928,"startTime":"0","endTime":"0","summary":"Niki BioSolutionsweighs financing options as going-concern warning clouds post-merger outlookOverviewUS biopharmaceutical developer's H1 net loss widened, with loss per share at $1.6Operating expenses","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","06996","IE00BZ08YT58.USD","BK1574","BK1191","BK1515","BK1521","BK1583","BK1587","NIKI","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1589","BK1161","02137","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":3,"totalSize":229,"code":"91000000","status":"200"}]}}